Taken together with the calculated t-erbB2 molecular mass, the expression of t-erbB2s (e.g., p110 isoforms) in HER2-positive breast cancer cells may enhance activation of MAPK signaling, supporting a role of t-erbB2s in drug resistance. This evidence concerns the gene ERBB2 and breast carcinoma.